Healthcare entity

Merck

Company MRK

Each story carries 47.7 original sources on average, compared with 4.3 for the broader beat in this window. At 7.7, the average consequence score sits above the same-window beat average of 6.2. Amgen is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories.

Last mentioned: Jul 16, 2026

Entity pulse

Recent coverage · Merck

3 stories
7.7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Merck

Each story carries 47.7 original sources on average, compared with 4.3 for the broader beat in this window. At 7.7, the average consequence score sits above the same-window beat average of 6.2. Amgen is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 127-day window averages about 0.2 stories each week. The clearest coverage concentration is acquisition: 1 of 3 stories, with the rest divided among 2 other categories. We currently track 3 Healthcare stories that mention Merck, published between March 12, 2026 and July 16, 2026.

Stories tracked
3
Per week
0.2
Sources per story
47.7

Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 490 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Merck. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Keytruda Patent Expiration

    The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.

  2. NXT 41X Launch

    Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.

  3. Pipeline Integration

    Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.

  4. Expected Closing

    Anticipated completion of the acquisition following regulatory and shareholder approvals.

  5. Bumble 2.0 Launch

    Targeted launch of AI-enabled platform experience.

  6. Acquisition Announced

    Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.

  7. Codexis CDMO Expansion

    Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.

  8. Elutia FDA Milestone

    Expected FDA submission for NXT 41X product line.

  9. Elutia Divestiture

    Completed $88M sale of bioenvelope business to Boston Scientific.

Stories mentioning Merck 3

Health IT Positive

MedTech and Life Sciences Pivot Toward AI Efficiency and Asset Optimization

The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.

9 sources

Merck is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.